Brain Scientific Inc. (BRSF) Tech to be Used in a Ketamine Clinical Study for Mental Health Care

  • Ehave announced it will utilize BRSF’s tech in an upcoming ketamine clinical study
  • BRSF’s tech will make it possible to correlate biomarkers for the identification of chronic pain, depression, PTSD, bipolar disorder, and more.
  • The data from this clinical trial has the potential to provide longitudinal insights that can link brain analysis and psychedelics

Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is on a mission to modernize brain diagnostics with cutting-edge tech that bridges the widening gap in access to quality care. The company’s technology will be part of a ketamine clinical study conducted by Ehave, Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. To read Ehave’s full announcement regarding the Ketamine Clinical Trial, go to

Ehave is a leading provider of digital therapeutics for the psychedelic and mental health sectors. The company’s primary goal is to improve standard care with digital therapeutics to prevent or treat…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.